nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—CYP2D6—Lomustine—brain cancer	0.0872	0.569	CbGbCtD
L-DOPA—CYP2D6—Hydroxyurea—brain cancer	0.0661	0.431	CbGbCtD
L-DOPA—DRD3—telencephalic ventricle—brain cancer	0.0171	0.0532	CbGeAlD
L-DOPA—DDC—telencephalic ventricle—brain cancer	0.0166	0.0518	CbGeAlD
L-DOPA—DDC—pineal body—brain cancer	0.0144	0.045	CbGeAlD
L-DOPA—PSIP1—hindbrain—brain cancer	0.0138	0.0429	CbGeAlD
L-DOPA—DRD1—telencephalic ventricle—brain cancer	0.0122	0.0381	CbGeAlD
L-DOPA—DDC—ganglion—brain cancer	0.0104	0.0323	CbGeAlD
L-DOPA—DRD5—ganglion—brain cancer	0.00996	0.031	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—brain cancer	0.00795	0.5	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—brain cancer	0.00795	0.5	CbGdCrCtD
L-DOPA—PSIP1—brainstem—brain cancer	0.0079	0.0246	CbGeAlD
L-DOPA—DDC—hindbrain—brain cancer	0.00786	0.0245	CbGeAlD
L-DOPA—DRD1—ganglion—brain cancer	0.00761	0.0237	CbGeAlD
L-DOPA—DRD2—telencephalic ventricle—brain cancer	0.00722	0.0225	CbGeAlD
L-DOPA—PSIP1—telencephalon—brain cancer	0.00701	0.0218	CbGeAlD
L-DOPA—PSIP1—gonad—brain cancer	0.00585	0.0182	CbGeAlD
L-DOPA—PSIP1—pituitary gland—brain cancer	0.00571	0.0178	CbGeAlD
L-DOPA—PSIP1—medulla oblongata—brain cancer	0.00551	0.0172	CbGeAlD
L-DOPA—PSIP1—midbrain—brain cancer	0.00503	0.0157	CbGeAlD
L-DOPA—PSIP1—spinal cord—brain cancer	0.00491	0.0153	CbGeAlD
L-DOPA—SLC7A8—telencephalon—brain cancer	0.00462	0.0144	CbGeAlD
L-DOPA—DDC—brainstem—brain cancer	0.0045	0.014	CbGeAlD
L-DOPA—DRD2—ganglion—brain cancer	0.0045	0.014	CbGeAlD
L-DOPA—PSIP1—endocrine gland—brain cancer	0.00442	0.0138	CbGeAlD
L-DOPA—PSIP1—head—brain cancer	0.00436	0.0136	CbGeAlD
L-DOPA—DDC—telencephalon—brain cancer	0.004	0.0124	CbGeAlD
L-DOPA—PSIP1—central nervous system—brain cancer	0.00398	0.0124	CbGeAlD
L-DOPA—PSIP1—cerebellum—brain cancer	0.00389	0.0121	CbGeAlD
L-DOPA—SLC7A8—gonad—brain cancer	0.00385	0.012	CbGeAlD
L-DOPA—DRD5—telencephalon—brain cancer	0.00384	0.012	CbGeAlD
L-DOPA—SLC7A8—pituitary gland—brain cancer	0.00376	0.0117	CbGeAlD
L-DOPA—SLC7A5—telencephalon—brain cancer	0.00358	0.0111	CbGeAlD
L-DOPA—DRD2—hindbrain—brain cancer	0.00341	0.0106	CbGeAlD
L-DOPA—DRD1—brainstem—brain cancer	0.00331	0.0103	CbGeAlD
L-DOPA—PSIP1—brain—brain cancer	0.00316	0.00985	CbGeAlD
L-DOPA—SLC7A5—gonad—brain cancer	0.00299	0.0093	CbGeAlD
L-DOPA—DRD1—telencephalon—brain cancer	0.00294	0.00915	CbGeAlD
L-DOPA—SLC7A5—pituitary gland—brain cancer	0.00291	0.00908	CbGeAlD
L-DOPA—SLC7A8—endocrine gland—brain cancer	0.00291	0.00907	CbGeAlD
L-DOPA—SLC7A8—head—brain cancer	0.00288	0.00896	CbGeAlD
L-DOPA—DDC—midbrain—brain cancer	0.00287	0.00894	CbGeAlD
L-DOPA—SLC7A5—medulla oblongata—brain cancer	0.00281	0.00876	CbGeAlD
L-DOPA—DRD4—brain—brain cancer	0.00263	0.0082	CbGeAlD
L-DOPA—SLC7A8—central nervous system—brain cancer	0.00263	0.00818	CbGeAlD
L-DOPA—SLC7A5—midbrain—brain cancer	0.00257	0.00801	CbGeAlD
L-DOPA—SLC7A8—cerebellum—brain cancer	0.00257	0.00799	CbGeAlD
L-DOPA—DRD3—head—brain cancer	0.00255	0.00795	CbGeAlD
L-DOPA—DDC—endocrine gland—brain cancer	0.00252	0.00785	CbGeAlD
L-DOPA—SLC7A5—spinal cord—brain cancer	0.00251	0.00781	CbGeAlD
L-DOPA—DDC—head—brain cancer	0.00249	0.00775	CbGeAlD
L-DOPA—DRD5—endocrine gland—brain cancer	0.00242	0.00755	CbGeAlD
L-DOPA—DRD5—head—brain cancer	0.00239	0.00745	CbGeAlD
L-DOPA—DRD3—central nervous system—brain cancer	0.00233	0.00726	CbGeAlD
L-DOPA—SLC16A10—gonad—brain cancer	0.00229	0.00712	CbGeAlD
L-DOPA—DDC—central nervous system—brain cancer	0.00227	0.00707	CbGeAlD
L-DOPA—SLC7A5—endocrine gland—brain cancer	0.00226	0.00703	CbGeAlD
L-DOPA—SLC7A5—head—brain cancer	0.00223	0.00694	CbGeAlD
L-DOPA—DRD5—central nervous system—brain cancer	0.00218	0.0068	CbGeAlD
L-DOPA—DRD1—midbrain—brain cancer	0.00211	0.00657	CbGeAlD
L-DOPA—SLC7A8—brain—brain cancer	0.00208	0.00649	CbGeAlD
L-DOPA—CYP2D6—hindbrain—brain cancer	0.00205	0.00638	CbGeAlD
L-DOPA—SLC7A5—central nervous system—brain cancer	0.00203	0.00634	CbGeAlD
L-DOPA—SLC7A5—cerebellum—brain cancer	0.00199	0.00619	CbGeAlD
L-DOPA—DRD2—brainstem—brain cancer	0.00195	0.00609	CbGeAlD
L-DOPA—SLC15A1—endocrine gland—brain cancer	0.00187	0.00584	CbGeAlD
L-DOPA—DRD3—brain—brain cancer	0.00185	0.00576	CbGeAlD
L-DOPA—DRD1—head—brain cancer	0.00183	0.0057	CbGeAlD
L-DOPA—DDC—brain—brain cancer	0.0018	0.00562	CbGeAlD
L-DOPA—Hot flush—Temozolomide—brain cancer	0.00176	0.00459	CcSEcCtD
L-DOPA—Flushing—Procarbazine—brain cancer	0.00175	0.00456	CcSEcCtD
L-DOPA—Menopausal symptoms—Temozolomide—brain cancer	0.00174	0.00455	CcSEcCtD
L-DOPA—DRD2—telencephalon—brain cancer	0.00173	0.0054	CbGeAlD
L-DOPA—DRD5—brain—brain cancer	0.00173	0.0054	CbGeAlD
L-DOPA—SLC16A10—endocrine gland—brain cancer	0.00173	0.00538	CbGeAlD
L-DOPA—Purpura—Temozolomide—brain cancer	0.00171	0.00445	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.0017	0.00444	CcSEcCtD
L-DOPA—Diplopia—Carmustine—brain cancer	0.0017	0.00444	CcSEcCtD
L-DOPA—Arrhythmia—Procarbazine—brain cancer	0.00168	0.00439	CcSEcCtD
L-DOPA—DRD1—central nervous system—brain cancer	0.00167	0.0052	CbGeAlD
L-DOPA—Alopecia—Procarbazine—brain cancer	0.00166	0.00434	CcSEcCtD
L-DOPA—Weight increased—Hydroxyurea—brain cancer	0.00166	0.00432	CcSEcCtD
L-DOPA—Diplopia—Temozolomide—brain cancer	0.00165	0.00429	CcSEcCtD
L-DOPA—SLC7A5—brain—brain cancer	0.00162	0.00503	CbGeAlD
L-DOPA—Tension—Procarbazine—brain cancer	0.00161	0.00419	CcSEcCtD
L-DOPA—Ataxia—Carmustine—brain cancer	0.0016	0.00418	CcSEcCtD
L-DOPA—Nervousness—Procarbazine—brain cancer	0.00159	0.00415	CcSEcCtD
L-DOPA—Neuropathy peripheral—Hydroxyurea—brain cancer	0.00159	0.00415	CcSEcCtD
L-DOPA—Ataxia—Temozolomide—brain cancer	0.00155	0.00404	CcSEcCtD
L-DOPA—Tremor—Procarbazine—brain cancer	0.00154	0.004	CcSEcCtD
L-DOPA—Phlebitis—Etoposide—brain cancer	0.00153	0.00399	CcSEcCtD
L-DOPA—SLC16A10—cerebellum—brain cancer	0.00152	0.00474	CbGeAlD
L-DOPA—Anaemia—Procarbazine—brain cancer	0.00151	0.00395	CcSEcCtD
L-DOPA—Dysphagia—Carmustine—brain cancer	0.00147	0.00384	CcSEcCtD
L-DOPA—Syncope—Procarbazine—brain cancer	0.00147	0.00383	CcSEcCtD
L-DOPA—Leukopenia—Procarbazine—brain cancer	0.00147	0.00383	CcSEcCtD
L-DOPA—Haemoglobin—Hydroxyurea—brain cancer	0.00146	0.00382	CcSEcCtD
L-DOPA—Haemorrhage—Hydroxyurea—brain cancer	0.00146	0.0038	CcSEcCtD
L-DOPA—Hallucination—Hydroxyurea—brain cancer	0.00145	0.00378	CcSEcCtD
L-DOPA—Loss of consciousness—Procarbazine—brain cancer	0.00144	0.00376	CcSEcCtD
L-DOPA—Cough—Procarbazine—brain cancer	0.00143	0.00373	CcSEcCtD
L-DOPA—Dysphagia—Temozolomide—brain cancer	0.00142	0.00371	CcSEcCtD
L-DOPA—Convulsion—Procarbazine—brain cancer	0.00142	0.0037	CcSEcCtD
L-DOPA—Hypertension—Procarbazine—brain cancer	0.00142	0.00369	CcSEcCtD
L-DOPA—DRD2—pituitary gland—brain cancer	0.00141	0.0044	CbGeAlD
L-DOPA—Anxiety—Procarbazine—brain cancer	0.00139	0.00363	CcSEcCtD
L-DOPA—Sweating increased—Temozolomide—brain cancer	0.00139	0.00361	CcSEcCtD
L-DOPA—Dry mouth—Procarbazine—brain cancer	0.00136	0.00356	CcSEcCtD
L-DOPA—Confusional state—Procarbazine—brain cancer	0.00135	0.00352	CcSEcCtD
L-DOPA—Vomiting—Lomustine—brain cancer	0.00134	0.00349	CcSEcCtD
L-DOPA—Oedema—Procarbazine—brain cancer	0.00134	0.00349	CcSEcCtD
L-DOPA—DRD1—brain—brain cancer	0.00133	0.00413	CbGeAlD
L-DOPA—Upper respiratory tract infection—Temozolomide—brain cancer	0.00132	0.00345	CcSEcCtD
L-DOPA—Shock—Procarbazine—brain cancer	0.00132	0.00343	CcSEcCtD
L-DOPA—Pollakiuria—Temozolomide—brain cancer	0.00131	0.00343	CcSEcCtD
L-DOPA—Thrombocytopenia—Procarbazine—brain cancer	0.00131	0.00342	CcSEcCtD
L-DOPA—Depression—Carmustine—brain cancer	0.00131	0.00341	CcSEcCtD
L-DOPA—Weight increased—Temozolomide—brain cancer	0.00129	0.00338	CcSEcCtD
L-DOPA—Hyperhidrosis—Procarbazine—brain cancer	0.00129	0.00337	CcSEcCtD
L-DOPA—Alopecia—Hydroxyurea—brain cancer	0.00129	0.00336	CcSEcCtD
L-DOPA—Weight decreased—Temozolomide—brain cancer	0.00129	0.00336	CcSEcCtD
L-DOPA—Neuropathy peripheral—Carmustine—brain cancer	0.00129	0.00335	CcSEcCtD
L-DOPA—Urinary tract infection—Carmustine—brain cancer	0.00128	0.00333	CcSEcCtD
L-DOPA—Anorexia—Procarbazine—brain cancer	0.00128	0.00333	CcSEcCtD
L-DOPA—Depression—Temozolomide—brain cancer	0.00126	0.0033	CcSEcCtD
L-DOPA—Nausea—Lomustine—brain cancer	0.00125	0.00326	CcSEcCtD
L-DOPA—Hypotension—Procarbazine—brain cancer	0.00125	0.00326	CcSEcCtD
L-DOPA—DRD2—midbrain—brain cancer	0.00125	0.00388	CbGeAlD
L-DOPA—Neuropathy peripheral—Temozolomide—brain cancer	0.00124	0.00324	CcSEcCtD
L-DOPA—Urinary tract infection—Temozolomide—brain cancer	0.00123	0.00321	CcSEcCtD
L-DOPA—Insomnia—Procarbazine—brain cancer	0.00121	0.00316	CcSEcCtD
L-DOPA—Paraesthesia—Procarbazine—brain cancer	0.0012	0.00313	CcSEcCtD
L-DOPA—Somnolence—Procarbazine—brain cancer	0.00119	0.0031	CcSEcCtD
L-DOPA—Cramp muscle—Etoposide—brain cancer	0.00119	0.00309	CcSEcCtD
L-DOPA—Haemoglobin—Carmustine—brain cancer	0.00118	0.00309	CcSEcCtD
L-DOPA—Haemorrhage—Carmustine—brain cancer	0.00118	0.00307	CcSEcCtD
L-DOPA—Ill-defined disorder—Hydroxyurea—brain cancer	0.00118	0.00307	CcSEcCtD
L-DOPA—CYP2D6—brainstem—brain cancer	0.00117	0.00366	CbGeAlD
L-DOPA—Anaemia—Hydroxyurea—brain cancer	0.00117	0.00306	CcSEcCtD
L-DOPA—Hypoaesthesia—Carmustine—brain cancer	0.00117	0.00306	CcSEcCtD
L-DOPA—Hallucination—Carmustine—brain cancer	0.00117	0.00306	CcSEcCtD
L-DOPA—Decreased appetite—Procarbazine—brain cancer	0.00116	0.00303	CcSEcCtD
L-DOPA—Fatigue—Procarbazine—brain cancer	0.00115	0.00301	CcSEcCtD
L-DOPA—Haemoglobin—Temozolomide—brain cancer	0.00114	0.00298	CcSEcCtD
L-DOPA—Malaise—Hydroxyurea—brain cancer	0.00114	0.00298	CcSEcCtD
L-DOPA—Constipation—Procarbazine—brain cancer	0.00114	0.00298	CcSEcCtD
L-DOPA—Pain—Procarbazine—brain cancer	0.00114	0.00298	CcSEcCtD
L-DOPA—Haemorrhage—Temozolomide—brain cancer	0.00114	0.00297	CcSEcCtD
L-DOPA—Dysphagia—Etoposide—brain cancer	0.00114	0.00297	CcSEcCtD
L-DOPA—Leukopenia—Hydroxyurea—brain cancer	0.00114	0.00296	CcSEcCtD
L-DOPA—Hallucination—Temozolomide—brain cancer	0.00113	0.00295	CcSEcCtD
L-DOPA—Hypoaesthesia—Temozolomide—brain cancer	0.00113	0.00295	CcSEcCtD
L-DOPA—Urinary tract disorder—Temozolomide—brain cancer	0.00112	0.00293	CcSEcCtD
L-DOPA—Urethral disorder—Temozolomide—brain cancer	0.00112	0.00291	CcSEcCtD
L-DOPA—Sweating increased—Etoposide—brain cancer	0.00111	0.00289	CcSEcCtD
L-DOPA—Feeling abnormal—Procarbazine—brain cancer	0.0011	0.00287	CcSEcCtD
L-DOPA—Convulsion—Hydroxyurea—brain cancer	0.0011	0.00287	CcSEcCtD
L-DOPA—DRD2—endocrine gland—brain cancer	0.00109	0.00341	CbGeAlD
L-DOPA—Gastrointestinal pain—Procarbazine—brain cancer	0.00109	0.00285	CcSEcCtD
L-DOPA—Flushing—Carmustine—brain cancer	0.00109	0.00285	CcSEcCtD
L-DOPA—DRD2—head—brain cancer	0.00108	0.00336	CbGeAlD
L-DOPA—Discomfort—Hydroxyurea—brain cancer	0.00107	0.00278	CcSEcCtD
L-DOPA—Urticaria—Procarbazine—brain cancer	0.00106	0.00277	CcSEcCtD
L-DOPA—Abdominal pain—Procarbazine—brain cancer	0.00106	0.00276	CcSEcCtD
L-DOPA—Flushing—Temozolomide—brain cancer	0.00106	0.00276	CcSEcCtD
L-DOPA—Arrhythmia—Carmustine—brain cancer	0.00105	0.00274	CcSEcCtD
L-DOPA—CYP2D6—telencephalon—brain cancer	0.00104	0.00325	CbGeAlD
L-DOPA—Alopecia—Carmustine—brain cancer	0.00104	0.00271	CcSEcCtD
L-DOPA—Oedema—Hydroxyurea—brain cancer	0.00104	0.0027	CcSEcCtD
L-DOPA—Mental disorder—Carmustine—brain cancer	0.00103	0.00269	CcSEcCtD
L-DOPA—Thrombocytopenia—Hydroxyurea—brain cancer	0.00101	0.00264	CcSEcCtD
L-DOPA—Alopecia—Temozolomide—brain cancer	0.00101	0.00262	CcSEcCtD
L-DOPA—Acute coronary syndrome—Etoposide—brain cancer	0.001	0.00261	CcSEcCtD
L-DOPA—Mental disorder—Temozolomide—brain cancer	0.000997	0.0026	CcSEcCtD
L-DOPA—Neuropathy peripheral—Etoposide—brain cancer	0.000995	0.00259	CcSEcCtD
L-DOPA—Myocardial infarction—Etoposide—brain cancer	0.000995	0.00259	CcSEcCtD
L-DOPA—Back pain—Carmustine—brain cancer	0.000992	0.00259	CcSEcCtD
L-DOPA—Anorexia—Hydroxyurea—brain cancer	0.000987	0.00257	CcSEcCtD
L-DOPA—DRD2—central nervous system—brain cancer	0.000986	0.00307	CbGeAlD
L-DOPA—Hypersensitivity—Procarbazine—brain cancer	0.000986	0.00257	CcSEcCtD
L-DOPA—Dysgeusia—Temozolomide—brain cancer	0.00097	0.00253	CcSEcCtD
L-DOPA—Vision blurred—Carmustine—brain cancer	0.000966	0.00252	CcSEcCtD
L-DOPA—DRD2—cerebellum—brain cancer	0.000964	0.003	CbGeAlD
L-DOPA—Tremor—Carmustine—brain cancer	0.000961	0.00251	CcSEcCtD
L-DOPA—Asthenia—Procarbazine—brain cancer	0.00096	0.0025	CcSEcCtD
L-DOPA—Back pain—Temozolomide—brain cancer	0.000959	0.0025	CcSEcCtD
L-DOPA—Anaemia—Carmustine—brain cancer	0.000948	0.00247	CcSEcCtD
L-DOPA—Agranulocytosis—Etoposide—brain cancer	0.000947	0.00247	CcSEcCtD
L-DOPA—Pruritus—Procarbazine—brain cancer	0.000946	0.00247	CcSEcCtD
L-DOPA—Agitation—Carmustine—brain cancer	0.000942	0.00246	CcSEcCtD
L-DOPA—Vision blurred—Temozolomide—brain cancer	0.000934	0.00244	CcSEcCtD
L-DOPA—Tremor—Temozolomide—brain cancer	0.000928	0.00242	CcSEcCtD
L-DOPA—Dyspnoea—Hydroxyurea—brain cancer	0.000923	0.00241	CcSEcCtD
L-DOPA—Somnolence—Hydroxyurea—brain cancer	0.00092	0.0024	CcSEcCtD
L-DOPA—Ill-defined disorder—Temozolomide—brain cancer	0.000919	0.0024	CcSEcCtD
L-DOPA—Leukopenia—Carmustine—brain cancer	0.000918	0.00239	CcSEcCtD
L-DOPA—Anaemia—Temozolomide—brain cancer	0.000916	0.00239	CcSEcCtD
L-DOPA—Diarrhoea—Procarbazine—brain cancer	0.000915	0.00239	CcSEcCtD
L-DOPA—Dyspepsia—Hydroxyurea—brain cancer	0.000911	0.00238	CcSEcCtD
L-DOPA—Agitation—Temozolomide—brain cancer	0.000911	0.00237	CcSEcCtD
L-DOPA—Hypoaesthesia—Etoposide—brain cancer	0.000906	0.00236	CcSEcCtD
L-DOPA—Angioedema—Temozolomide—brain cancer	0.000905	0.00236	CcSEcCtD
L-DOPA—Decreased appetite—Hydroxyurea—brain cancer	0.0009	0.00235	CcSEcCtD
L-DOPA—Urinary tract disorder—Etoposide—brain cancer	0.0009	0.00235	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000894	0.00233	CcSEcCtD
L-DOPA—Malaise—Temozolomide—brain cancer	0.000894	0.00233	CcSEcCtD
L-DOPA—Urethral disorder—Etoposide—brain cancer	0.000893	0.00233	CcSEcCtD
L-DOPA—Fatigue—Hydroxyurea—brain cancer	0.000893	0.00233	CcSEcCtD
L-DOPA—Convulsion—Carmustine—brain cancer	0.000888	0.00232	CcSEcCtD
L-DOPA—Leukopenia—Temozolomide—brain cancer	0.000887	0.00231	CcSEcCtD
L-DOPA—Hypertension—Carmustine—brain cancer	0.000885	0.00231	CcSEcCtD
L-DOPA—Pain—Hydroxyurea—brain cancer	0.000885	0.00231	CcSEcCtD
L-DOPA—Constipation—Hydroxyurea—brain cancer	0.000885	0.00231	CcSEcCtD
L-DOPA—Dizziness—Procarbazine—brain cancer	0.000885	0.00231	CcSEcCtD
L-DOPA—Palpitations—Temozolomide—brain cancer	0.000876	0.00228	CcSEcCtD
L-DOPA—Chest pain—Carmustine—brain cancer	0.000873	0.00228	CcSEcCtD
L-DOPA—Anxiety—Carmustine—brain cancer	0.00087	0.00227	CcSEcCtD
L-DOPA—Cough—Temozolomide—brain cancer	0.000865	0.00226	CcSEcCtD
L-DOPA—Convulsion—Temozolomide—brain cancer	0.000859	0.00224	CcSEcCtD
L-DOPA—Hypertension—Temozolomide—brain cancer	0.000856	0.00223	CcSEcCtD
L-DOPA—Feeling abnormal—Hydroxyurea—brain cancer	0.000853	0.00222	CcSEcCtD
L-DOPA—Vomiting—Procarbazine—brain cancer	0.000851	0.00222	CcSEcCtD
L-DOPA—Flushing—Etoposide—brain cancer	0.000845	0.0022	CcSEcCtD
L-DOPA—Confusional state—Carmustine—brain cancer	0.000844	0.0022	CcSEcCtD
L-DOPA—Rash—Procarbazine—brain cancer	0.000843	0.0022	CcSEcCtD
L-DOPA—Dermatitis—Procarbazine—brain cancer	0.000843	0.0022	CcSEcCtD
L-DOPA—Anxiety—Temozolomide—brain cancer	0.000841	0.00219	CcSEcCtD
L-DOPA—Headache—Procarbazine—brain cancer	0.000838	0.00219	CcSEcCtD
L-DOPA—Oedema—Carmustine—brain cancer	0.000837	0.00218	CcSEcCtD
L-DOPA—Discomfort—Temozolomide—brain cancer	0.000834	0.00217	CcSEcCtD
L-DOPA—Dry mouth—Temozolomide—brain cancer	0.000825	0.00215	CcSEcCtD
L-DOPA—Thrombocytopenia—Carmustine—brain cancer	0.000819	0.00214	CcSEcCtD
L-DOPA—Confusional state—Temozolomide—brain cancer	0.000815	0.00213	CcSEcCtD
L-DOPA—Oedema—Temozolomide—brain cancer	0.000809	0.00211	CcSEcCtD
L-DOPA—Alopecia—Etoposide—brain cancer	0.000805	0.0021	CcSEcCtD
L-DOPA—Anorexia—Carmustine—brain cancer	0.000798	0.00208	CcSEcCtD
L-DOPA—Nausea—Procarbazine—brain cancer	0.000795	0.00207	CcSEcCtD
L-DOPA—Thrombocytopenia—Temozolomide—brain cancer	0.000792	0.00207	CcSEcCtD
L-DOPA—DRD2—brain—brain cancer	0.000783	0.00244	CbGeAlD
L-DOPA—Hypotension—Carmustine—brain cancer	0.000782	0.00204	CcSEcCtD
L-DOPA—Hyperhidrosis—Temozolomide—brain cancer	0.000782	0.00204	CcSEcCtD
L-DOPA—Dysgeusia—Etoposide—brain cancer	0.000777	0.00203	CcSEcCtD
L-DOPA—Anorexia—Temozolomide—brain cancer	0.000771	0.00201	CcSEcCtD
L-DOPA—Back pain—Etoposide—brain cancer	0.000767	0.002	CcSEcCtD
L-DOPA—Hypersensitivity—Hydroxyurea—brain cancer	0.000763	0.00199	CcSEcCtD
L-DOPA—Muscle spasms—Etoposide—brain cancer	0.000762	0.00199	CcSEcCtD
L-DOPA—Insomnia—Carmustine—brain cancer	0.000757	0.00197	CcSEcCtD
L-DOPA—Paraesthesia—Carmustine—brain cancer	0.000752	0.00196	CcSEcCtD
L-DOPA—Dyspnoea—Carmustine—brain cancer	0.000746	0.00195	CcSEcCtD
L-DOPA—Somnolence—Carmustine—brain cancer	0.000744	0.00194	CcSEcCtD
L-DOPA—Asthenia—Hydroxyurea—brain cancer	0.000743	0.00194	CcSEcCtD
L-DOPA—Ill-defined disorder—Etoposide—brain cancer	0.000736	0.00192	CcSEcCtD
L-DOPA—Anaemia—Etoposide—brain cancer	0.000733	0.00191	CcSEcCtD
L-DOPA—Insomnia—Temozolomide—brain cancer	0.000732	0.00191	CcSEcCtD
L-DOPA—Decreased appetite—Carmustine—brain cancer	0.000728	0.0019	CcSEcCtD
L-DOPA—Paraesthesia—Temozolomide—brain cancer	0.000726	0.00189	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Carmustine—brain cancer	0.000723	0.00188	CcSEcCtD
L-DOPA—Dyspnoea—Temozolomide—brain cancer	0.000721	0.00188	CcSEcCtD
L-DOPA—Somnolence—Temozolomide—brain cancer	0.000719	0.00188	CcSEcCtD
L-DOPA—Constipation—Carmustine—brain cancer	0.000716	0.00187	CcSEcCtD
L-DOPA—Pain—Carmustine—brain cancer	0.000716	0.00187	CcSEcCtD
L-DOPA—Malaise—Etoposide—brain cancer	0.000715	0.00186	CcSEcCtD
L-DOPA—Dyspepsia—Temozolomide—brain cancer	0.000712	0.00186	CcSEcCtD
L-DOPA—Leukopenia—Etoposide—brain cancer	0.00071	0.00185	CcSEcCtD
L-DOPA—Diarrhoea—Hydroxyurea—brain cancer	0.000708	0.00185	CcSEcCtD
L-DOPA—Decreased appetite—Temozolomide—brain cancer	0.000703	0.00183	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Temozolomide—brain cancer	0.000698	0.00182	CcSEcCtD
L-DOPA—Fatigue—Temozolomide—brain cancer	0.000697	0.00182	CcSEcCtD
L-DOPA—Loss of consciousness—Etoposide—brain cancer	0.000697	0.00182	CcSEcCtD
L-DOPA—Cough—Etoposide—brain cancer	0.000692	0.0018	CcSEcCtD
L-DOPA—Pain—Temozolomide—brain cancer	0.000692	0.0018	CcSEcCtD
L-DOPA—Constipation—Temozolomide—brain cancer	0.000692	0.0018	CcSEcCtD
L-DOPA—Feeling abnormal—Carmustine—brain cancer	0.00069	0.0018	CcSEcCtD
L-DOPA—Convulsion—Etoposide—brain cancer	0.000687	0.00179	CcSEcCtD
L-DOPA—Hypertension—Etoposide—brain cancer	0.000685	0.00179	CcSEcCtD
L-DOPA—Dizziness—Hydroxyurea—brain cancer	0.000685	0.00179	CcSEcCtD
L-DOPA—Gastrointestinal pain—Carmustine—brain cancer	0.000684	0.00178	CcSEcCtD
L-DOPA—Chest pain—Etoposide—brain cancer	0.000675	0.00176	CcSEcCtD
L-DOPA—Discomfort—Etoposide—brain cancer	0.000667	0.00174	CcSEcCtD
L-DOPA—Feeling abnormal—Temozolomide—brain cancer	0.000666	0.00174	CcSEcCtD
L-DOPA—Abdominal pain—Carmustine—brain cancer	0.000662	0.00173	CcSEcCtD
L-DOPA—Gastrointestinal pain—Temozolomide—brain cancer	0.000661	0.00172	CcSEcCtD
L-DOPA—Vomiting—Hydroxyurea—brain cancer	0.000658	0.00172	CcSEcCtD
L-DOPA—CYP2D6—endocrine gland—brain cancer	0.000658	0.00205	CbGeAlD
L-DOPA—Rash—Hydroxyurea—brain cancer	0.000653	0.0017	CcSEcCtD
L-DOPA—Confusional state—Etoposide—brain cancer	0.000653	0.0017	CcSEcCtD
L-DOPA—Dermatitis—Hydroxyurea—brain cancer	0.000652	0.0017	CcSEcCtD
L-DOPA—CYP2D6—head—brain cancer	0.000649	0.00202	CbGeAlD
L-DOPA—Headache—Hydroxyurea—brain cancer	0.000649	0.00169	CcSEcCtD
L-DOPA—Urticaria—Temozolomide—brain cancer	0.000643	0.00168	CcSEcCtD
L-DOPA—Abdominal pain—Temozolomide—brain cancer	0.000639	0.00167	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—brain cancer	0.000634	0.00165	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—brain cancer	0.000626	0.00163	CcSEcCtD
L-DOPA—Anorexia—Etoposide—brain cancer	0.000617	0.00161	CcSEcCtD
L-DOPA—Hypersensitivity—Carmustine—brain cancer	0.000617	0.00161	CcSEcCtD
L-DOPA—Nausea—Hydroxyurea—brain cancer	0.000615	0.0016	CcSEcCtD
L-DOPA—Hypotension—Etoposide—brain cancer	0.000605	0.00158	CcSEcCtD
L-DOPA—Asthenia—Carmustine—brain cancer	0.0006	0.00157	CcSEcCtD
L-DOPA—Dopamine—CYP2C9—brain cancer	0.000598	0.506	CrCbGaD
L-DOPA—Hypersensitivity—Temozolomide—brain cancer	0.000596	0.00155	CcSEcCtD
L-DOPA—CYP2D6—central nervous system—brain cancer	0.000593	0.00185	CbGeAlD
L-DOPA—Epinephrine—CYP2C9—brain cancer	0.000583	0.494	CrCbGaD
L-DOPA—Paraesthesia—Etoposide—brain cancer	0.000581	0.00152	CcSEcCtD
L-DOPA—Asthenia—Temozolomide—brain cancer	0.00058	0.00151	CcSEcCtD
L-DOPA—CYP2D6—cerebellum—brain cancer	0.000579	0.0018	CbGeAlD
L-DOPA—Dyspnoea—Etoposide—brain cancer	0.000577	0.0015	CcSEcCtD
L-DOPA—Somnolence—Etoposide—brain cancer	0.000575	0.0015	CcSEcCtD
L-DOPA—Diarrhoea—Carmustine—brain cancer	0.000573	0.00149	CcSEcCtD
L-DOPA—Pruritus—Temozolomide—brain cancer	0.000572	0.00149	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—brain cancer	0.000563	0.00147	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—brain cancer	0.000559	0.00146	CcSEcCtD
L-DOPA—Fatigue—Etoposide—brain cancer	0.000558	0.00146	CcSEcCtD
L-DOPA—Dizziness—Carmustine—brain cancer	0.000553	0.00144	CcSEcCtD
L-DOPA—Pain—Etoposide—brain cancer	0.000553	0.00144	CcSEcCtD
L-DOPA—Constipation—Etoposide—brain cancer	0.000553	0.00144	CcSEcCtD
L-DOPA—Diarrhoea—Temozolomide—brain cancer	0.000553	0.00144	CcSEcCtD
L-DOPA—Dizziness—Temozolomide—brain cancer	0.000535	0.00139	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—brain cancer	0.000533	0.00139	CcSEcCtD
L-DOPA—Vomiting—Carmustine—brain cancer	0.000532	0.00139	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—brain cancer	0.000529	0.00138	CcSEcCtD
L-DOPA—Rash—Carmustine—brain cancer	0.000528	0.00138	CcSEcCtD
L-DOPA—Dermatitis—Carmustine—brain cancer	0.000527	0.00137	CcSEcCtD
L-DOPA—Headache—Carmustine—brain cancer	0.000524	0.00137	CcSEcCtD
L-DOPA—Vomiting—Temozolomide—brain cancer	0.000514	0.00134	CcSEcCtD
L-DOPA—Urticaria—Etoposide—brain cancer	0.000514	0.00134	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—brain cancer	0.000512	0.00133	CcSEcCtD
L-DOPA—Rash—Temozolomide—brain cancer	0.00051	0.00133	CcSEcCtD
L-DOPA—Dermatitis—Temozolomide—brain cancer	0.000509	0.00133	CcSEcCtD
L-DOPA—Headache—Temozolomide—brain cancer	0.000507	0.00132	CcSEcCtD
L-DOPA—Nausea—Carmustine—brain cancer	0.000497	0.0013	CcSEcCtD
L-DOPA—Nausea—Temozolomide—brain cancer	0.00048	0.00125	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—brain cancer	0.000477	0.00124	CcSEcCtD
L-DOPA—CYP2D6—brain—brain cancer	0.00047	0.00147	CbGeAlD
L-DOPA—Asthenia—Etoposide—brain cancer	0.000464	0.00121	CcSEcCtD
L-DOPA—Pruritus—Etoposide—brain cancer	0.000458	0.00119	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—brain cancer	0.000443	0.00115	CcSEcCtD
L-DOPA—Dizziness—Etoposide—brain cancer	0.000428	0.00112	CcSEcCtD
L-DOPA—Vomiting—Etoposide—brain cancer	0.000411	0.00107	CcSEcCtD
L-DOPA—Rash—Etoposide—brain cancer	0.000408	0.00106	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—brain cancer	0.000408	0.00106	CcSEcCtD
L-DOPA—Headache—Etoposide—brain cancer	0.000405	0.00106	CcSEcCtD
L-DOPA—Nausea—Etoposide—brain cancer	0.000384	0.001	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—IL2—brain cancer	0.000155	0.00124	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SHH—brain cancer	0.000155	0.00124	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ABR—brain cancer	0.000155	0.00124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DTX2—brain cancer	0.000154	0.00123	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SHH—brain cancer	0.000152	0.00121	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—VEGFA—brain cancer	0.000151	0.00121	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH2—brain cancer	0.000151	0.00121	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—TRPC6—brain cancer	0.000149	0.00119	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—brain cancer	0.000149	0.00119	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTCH1—brain cancer	0.000147	0.00117	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SMO—brain cancer	0.000147	0.00117	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ERBB2—brain cancer	0.000146	0.00116	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTCH1—brain cancer	0.000144	0.00115	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SMO—brain cancer	0.000144	0.00115	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ABR—brain cancer	0.000139	0.00111	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ENO2—brain cancer	0.000139	0.00111	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—OR14C36—brain cancer	0.000138	0.00111	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—OR4C12—brain cancer	0.000138	0.00111	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CDK4—brain cancer	0.000138	0.0011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GLI2—brain cancer	0.000135	0.00108	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—VEGFA—brain cancer	0.000132	0.00105	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH2—brain cancer	0.000131	0.00105	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ABR—brain cancer	0.00013	0.00104	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CTNNB1—brain cancer	0.000127	0.00102	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HES5—brain cancer	0.000127	0.00102	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GLI1—brain cancer	0.000127	0.00101	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STRADA—brain cancer	0.000123	0.000986	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—VAV1—brain cancer	0.000123	0.000986	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—TRPC6—brain cancer	0.000121	0.000971	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SUFU—brain cancer	0.00012	0.00096	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ABR—brain cancer	0.000118	0.000947	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH2—brain cancer	0.000118	0.000944	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DTX2—brain cancer	0.000118	0.00094	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH2—brain cancer	0.000117	0.000931	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GFAP—brain cancer	0.000116	0.000926	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SHH—brain cancer	0.000114	0.000914	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HES5—brain cancer	0.000114	0.000914	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—brain cancer	0.000114	0.000913	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HES5—brain cancer	0.000113	0.000902	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—VAV1—brain cancer	0.000112	0.000895	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STRADA—brain cancer	0.000111	0.000888	CbGpPWpGaD
L-DOPA—PSIP1—Disease—STAT3—brain cancer	0.000111	0.000888	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TRPC6—brain cancer	0.00011	0.000882	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HEY1—brain cancer	0.00011	0.000878	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STRADA—brain cancer	0.00011	0.000876	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—TRPC6—brain cancer	0.000109	0.000874	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SMO—brain cancer	0.000108	0.000867	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTCH1—brain cancer	0.000108	0.000867	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—TRPC6—brain cancer	0.000108	0.000863	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DLL1—brain cancer	0.000108	0.000861	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MYC—brain cancer	0.000103	0.000825	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SHH—brain cancer	0.000103	0.000823	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ABR—brain cancer	0.000103	0.000823	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SHH—brain cancer	0.000102	0.000812	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—brain cancer	0.000101	0.000807	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—brain cancer	9.96e-05	0.000796	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GLI2—brain cancer	9.94e-05	0.000795	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TRPC6—brain cancer	9.93e-05	0.000794	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TRPC6—brain cancer	9.8e-05	0.000783	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SMO—brain cancer	9.76e-05	0.00078	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTCH1—brain cancer	9.76e-05	0.00078	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SMO—brain cancer	9.63e-05	0.00077	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTCH1—brain cancer	9.63e-05	0.00077	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GLI1—brain cancer	9.35e-05	0.000747	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ABR—brain cancer	9.27e-05	0.000741	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SHH—brain cancer	9.16e-05	0.000732	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ABR—brain cancer	9.14e-05	0.000731	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—VAV1—brain cancer	9.1e-05	0.000728	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GLI2—brain cancer	8.95e-05	0.000715	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH2—brain cancer	8.92e-05	0.000713	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SUFU—brain cancer	8.86e-05	0.000708	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GLI2—brain cancer	8.83e-05	0.000706	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TRPC6—brain cancer	8.83e-05	0.000706	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTCH1—brain cancer	8.68e-05	0.000694	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMO—brain cancer	8.68e-05	0.000694	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—brain cancer	8.65e-05	0.000691	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES5—brain cancer	8.64e-05	0.00069	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GFAP—brain cancer	8.55e-05	0.000683	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GLI1—brain cancer	8.41e-05	0.000673	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STRADA—brain cancer	8.38e-05	0.00067	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GLI1—brain cancer	8.3e-05	0.000664	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—VAV1—brain cancer	8.26e-05	0.000661	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—TRPC6—brain cancer	8.26e-05	0.00066	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—VAV1—brain cancer	8.19e-05	0.000655	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HEY1—brain cancer	8.1e-05	0.000648	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—VAV1—brain cancer	8.08e-05	0.000646	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SUFU—brain cancer	7.98e-05	0.000638	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DLL1—brain cancer	7.95e-05	0.000635	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SUFU—brain cancer	7.87e-05	0.000629	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CG—brain cancer	7.83e-05	0.000626	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—brain cancer	7.79e-05	0.000622	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SHH—brain cancer	7.78e-05	0.000622	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GFAP—brain cancer	7.7e-05	0.000615	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—brain cancer	7.68e-05	0.000614	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GFAP—brain cancer	7.59e-05	0.000607	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TRPC6—brain cancer	7.5e-05	0.000599	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—VAV1—brain cancer	7.44e-05	0.000595	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH1—brain cancer	7.37e-05	0.000589	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SMO—brain cancer	7.37e-05	0.000589	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—VAV1—brain cancer	7.34e-05	0.000587	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HEY1—brain cancer	7.3e-05	0.000583	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HEY1—brain cancer	7.2e-05	0.000575	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DLL1—brain cancer	7.15e-05	0.000572	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CG—brain cancer	7.11e-05	0.000568	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DLL1—brain cancer	7.06e-05	0.000564	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ABR—brain cancer	7e-05	0.000559	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH2—brain cancer	6.94e-05	0.000555	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SHH—brain cancer	6.76e-05	0.00054	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GLI2—brain cancer	6.76e-05	0.00054	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VAV1—brain cancer	6.62e-05	0.000529	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TRPC6—brain cancer	6.52e-05	0.000521	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMO—brain cancer	6.41e-05	0.000512	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH1—brain cancer	6.41e-05	0.000512	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CG—brain cancer	6.39e-05	0.000511	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GLI1—brain cancer	6.35e-05	0.000508	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—VAV1—brain cancer	6.19e-05	0.000495	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SHH—brain cancer	6.08e-05	0.000486	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SUFU—brain cancer	6.02e-05	0.000481	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SHH—brain cancer	6e-05	0.00048	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—brain cancer	5.88e-05	0.00047	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TRPC6—brain cancer	5.87e-05	0.000469	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GFAP—brain cancer	5.81e-05	0.000465	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TRPC6—brain cancer	5.79e-05	0.000463	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CG—brain cancer	5.78e-05	0.000462	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH1—brain cancer	5.77e-05	0.000461	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMO—brain cancer	5.77e-05	0.000461	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH1—brain cancer	5.69e-05	0.000455	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMO—brain cancer	5.69e-05	0.000455	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HES1—brain cancer	5.69e-05	0.000455	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—VAV1—brain cancer	5.62e-05	0.000449	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2C9—brain cancer	5.54e-05	0.000443	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—brain cancer	5.51e-05	0.00044	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HEY1—brain cancer	5.51e-05	0.00044	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PDGFRA—brain cancer	5.42e-05	0.000433	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DLL1—brain cancer	5.4e-05	0.000432	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SPP1—brain cancer	5.26e-05	0.00042	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CG—brain cancer	5.25e-05	0.00042	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CG—brain cancer	5.2e-05	0.000416	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CG—brain cancer	5.13e-05	0.00041	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH2—brain cancer	5.12e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—brain cancer	5e-05	0.0004	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VAV1—brain cancer	4.88e-05	0.00039	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IRS2—brain cancer	4.76e-05	0.00038	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CG—brain cancer	4.72e-05	0.000378	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BSG—brain cancer	4.71e-05	0.000377	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CG—brain cancer	4.66e-05	0.000373	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH2—brain cancer	4.61e-05	0.000369	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SHH—brain cancer	4.59e-05	0.000367	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH2—brain cancer	4.55e-05	0.000364	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TRPC6—brain cancer	4.43e-05	0.000354	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VAV1—brain cancer	4.4e-05	0.000351	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMO—brain cancer	4.35e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH1—brain cancer	4.35e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VAV1—brain cancer	4.34e-05	0.000347	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CG—brain cancer	4.2e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APC—brain cancer	4.2e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HES1—brain cancer	4.2e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—brain cancer	4.07e-05	0.000325	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—IDH1—brain cancer	4.05e-05	0.000324	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDGFRA—brain cancer	4e-05	0.00032	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CG—brain cancer	3.93e-05	0.000314	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SPP1—brain cancer	3.88e-05	0.00031	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—brain cancer	3.83e-05	0.000306	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HES1—brain cancer	3.78e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HES1—brain cancer	3.73e-05	0.000298	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—brain cancer	3.69e-05	0.000295	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—brain cancer	3.66e-05	0.000293	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—brain cancer	3.61e-05	0.000289	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFRA—brain cancer	3.6e-05	0.000288	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CG—brain cancer	3.57e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFRA—brain cancer	3.55e-05	0.000284	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IRS2—brain cancer	3.51e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SPP1—brain cancer	3.49e-05	0.000279	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH2—brain cancer	3.48e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SPP1—brain cancer	3.45e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—brain cancer	3.32e-05	0.000266	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VAV1—brain cancer	3.32e-05	0.000265	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RELA—brain cancer	3.28e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—brain cancer	3.28e-05	0.000262	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—brain cancer	3.26e-05	0.000261	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—brain cancer	3.2e-05	0.000256	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IRS2—brain cancer	3.16e-05	0.000253	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IRS2—brain cancer	3.12e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CG—brain cancer	3.1e-05	0.000248	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APC—brain cancer	3.1e-05	0.000248	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—brain cancer	2.96e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—brain cancer	2.88e-05	0.00023	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—brain cancer	2.85e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—brain cancer	2.85e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—brain cancer	2.82e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—brain cancer	2.79e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—brain cancer	2.79e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—brain cancer	2.76e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—brain cancer	2.75e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—brain cancer	2.75e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRA—brain cancer	2.72e-05	0.000217	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—brain cancer	2.64e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—brain cancer	2.54e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—brain cancer	2.51e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—brain cancer	2.51e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—brain cancer	2.51e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—brain cancer	2.49e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RELA—brain cancer	2.42e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—brain cancer	2.41e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IRS2—brain cancer	2.39e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—brain cancer	2.31e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—brain cancer	2.26e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—brain cancer	2.18e-05	0.000174	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RELA—brain cancer	2.18e-05	0.000174	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—brain cancer	2.17e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RELA—brain cancer	2.15e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—brain cancer	2.14e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—brain cancer	2.13e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—brain cancer	2.11e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—brain cancer	2.11e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—brain cancer	2.11e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—brain cancer	1.96e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—brain cancer	1.94e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—brain cancer	1.92e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—brain cancer	1.91e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—brain cancer	1.9e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—brain cancer	1.9e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—brain cancer	1.89e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—brain cancer	1.87e-05	0.00015	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—brain cancer	1.85e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—brain cancer	1.84e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—brain cancer	1.71e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—brain cancer	1.67e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—brain cancer	1.67e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—brain cancer	1.65e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—brain cancer	1.65e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RELA—brain cancer	1.65e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—brain cancer	1.64e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—brain cancer	1.63e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—brain cancer	1.54e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—brain cancer	1.52e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—brain cancer	1.5e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—brain cancer	1.48e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—brain cancer	1.48e-05	0.000118	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—brain cancer	1.47e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—brain cancer	1.45e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—brain cancer	1.43e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—brain cancer	1.4e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—brain cancer	1.26e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—brain cancer	1.26e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—brain cancer	1.25e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—brain cancer	1.24e-05	9.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—brain cancer	1.16e-05	9.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—brain cancer	1.13e-05	9.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—brain cancer	9.52e-06	7.61e-05	CbGpPWpGaD
